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Abstract
Background: The clinical benefit of gemcitabine, the standard systemic therapy of pancreatic cancer
(PaCa), remains modest as a result of high chemoresistance. The proteasome inhibitor bortezomib has
antitumour activity against PaCa in vitro and in vivo. We examined the antitumour activity of combination
PaCa therapy with bortezomib and gemcitabine.
Methods: Cell proliferation assays were performed using WST-1 reagent. Protein expression was deter-
mined by Western blotting. Efficacy of bortezomib and/or gemcitabine was tested in vivo in a survival
study.
Results: Bortezomib at 10 mM caused 29% and 72% inhibition in AsPC-1 PaCa cell proliferation at 48
and 96 h incubation, respectively. Bortezomib was even more active against PaCa cell lines Panc-1 and
MiaPaCa, with 80% inhibition of proliferation at 48 h. The combination of bortezomib and gemcitabine
inhibited AsPC-1 proliferation more effectively compared with each single agent alone. Poly(ADP-ribose)
polymerase (PARP) cleavage, an apoptotic indicator, reached 6.6-, 2- and 8.5-fold over controls for
bortezomib, gemcitabine and the combination. The median survival was 31 (controls and bortezomib), 40
(gemcitabine) and 48 days (combination), respectively (P < 0.002).
Conclusions: Bortezomib and gemcitabine demonstrate additive antitumour activity in vitro and in an
experimental PaCa model, indicating the potential for clinical PaCa benefits of additional multiagent
therapies that will be based upon the bortezomib and gemcitabine combination.
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Introduction
Pancreatic cancer (PaCa) is a highly lethal cancer and remains the
fourth leading cause of cancer deaths in both men and women.1
The incidence of PaCa in the US has risen slowly with nearly
38,000 cases a year diagnosed, and fewer than 5% of patients
survive beyond 5 years. Late diagnosis and early onset of metasta-
sis limit curative resection to <10% of patients. In addition, PaCa
is highly resistant to chemotherapy. Gemcitabine is currently the
only standard chemotherapeutic drug in use for advanced PaCa
with a median survival rate of approximately 6 months.2
Combination treatment of gemcitabine with other chemotherapy
agents or with angiogenesis inhibitors failed to show any signifi-
cant survival benefit in PaCa patients.3–6 Therefore, the require-
ment for novel andmore effective treatment strategies for patients
with advanced PaCa is urgent.
The 26S proteasome is a large multicatalytic cytoplasmic and
nuclear protease complex that is responsible for most nonlysoso-
mal cellular protein degradation. Proteasomal protein degrada-
tion is critical for the regulation of several cellular functions such
as protein turnover, cell cycle control, signal transduction, tran-
scription regulation, apoptosis, antigen presentation and selective
removal of abnormal proteins.7 Inhibition of the proteasome
results in stabilization and accumulation of proteasome
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substrates, leading to antiproliferative, proapoptotic and antian-
giogenic effects. Therefore, proteasome inhibition represents a
novel therapeutic strategy for cancer treatment. Bortezomib, a
specific and selective inhibitor of the proteasome, is an approved
drug for treatment of multiple myloma. Bortezomib is currently
under investigation for treatment of various cancers primarily in
combination therapy, as single agent bortezomib has lower activ-
ity in solid tumours.8,9 In PaCa, several preclinical studies have
shown antitumour effects of bortezomib, alone or in combination
with other chemotherapy agents including gemcitabine.10–12 Com-
bination benefits of bortezomib with gemcitabine in these pre-
clinical models of PaCa have shown to be critically dependent
on the dose schedule of proteasome inhibition and
chemotherapy.13–15 In a phase II clinical trial bortezomib and gem-
citabine therapy was given according to the study of Nawrocki
et al.15 with two cycles of bortezomib and one cycle of gemcitab-
ine, but no benefit was observed compared with gemcitabine
alone in other studies.16 The discrepency between preclinical
results and the limited clinical evaluation of combination therapy
to date suggest a possible benefit through optimization of bort-
ezomib and gemcitabine treatment conditions; in addition, analy-
sis of the combination therapy mechanism of action may allow
evaluation of how therapeutic targets of relevance for additional
antitumor agents are affected, which could yield future combina-
tions with increased treatment efficacy for PaCa. In the present
study, we evaluated in vitro effects of bortezomib and gemcitabine
on PaCa cell proliferation and apoptosis to analyse the cellular
response mechanism.We also evaluated effects of bortezomib and
gemcitabine treatment on in vivo animal survival with mainte-
nance combination therapy in murine PaCa xenografts.
Material and methods
Cell culture and reagents
The human PaCa cell lines AsPC-1, Panc-1 and MiaPaCa were
obtained from the American Type Culture Collection (ATCC,
Rockville, MD). AsPC-1 cells were grown in RPMI-1640 medium
(Sigma, St. Louis, MO, USA), and Panc-1 and MiaPaCa cells were
grown in Dulbecco’s modified Eagle medium (DMEM). Media
contained 10% foetal bovine serum (FBS) and 100 U/ml
penicillin/streptomycin solution (Sigma). The cytotoxic agent
gemcitabine was purchased from Eli Lilly Corporation (India-
napolis, IN, USA), and bortezomib was purchased from Millen-
nium Pharmaceuticals (Boston, MA, USA).
In vitro cell proliferation assay
Cell proliferation was evaluated by the colorimetric WST-1 assay.
The measurement is based on the ability of viable cells to cleave
the sulfonated tetrazolium salt WST-1 by mitochondrial dehydro-
genases. PaCa cells (4000 cells per well) were plated in a 96-well
plate in regular growth medium. After 16 h the medium was
replaced with 2% FBS containing respective medium. After 5 h
incubation, the cells were treated with bortezomib and gemcitab-
ine, either alone or in combination. After additional incubation of
48, 72 or 96 h, 10 ml of WST-1 reagent was added in each well
followed by incubation for 2 h. The absorbance at 450 nm was
measured using a microplate reader.
Western blot analysis
A monolayer of cells at 75% to 80% confluence was placed in 2%
FBS containing medium for at least 5 h before treatment with
bortezomib (10 mM) and gemcitabine (10 mM) for 24 h. Cells
were collected and lysed as previously described.17 Equal amounts
of total protein were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to polyvinylidene fluoride (PVDF) membranes (Bio-Rad, Her-
cules, CA,USA). The membranes were blocked for 1 hour at room
temperature with gentle shaking in Tris-buffered saline Tween 20
(TBS-T). The membranes were incubated overnight at 4°C with
the anti-poly(ADP-ribose) polymerase (PARP)-1 (Santa Cruz
Biotechnologies, Santa Cruz, CA, USA) or anti-a-tubulin (Sigma)
antibodies and then incubated with corresponding HRP-
conjugated secondary antibodies. Specific bands were detected
using the enhanced chemiluminescence reagent (ECL; Perkin
Elmer Life Sciences, Boston, MA, USA) on autoradiographic film
and quantitated by densitometry.
Animal survival study
An animal survival assay was conducted as described earlier.18
Female severe combined immunodeficiency (SCID) mice received
AsPC-1 cells (0.75 ¥ 106 per animal) intraperitoneally. Twelve days
after tumour cell injection, mice were randomly divided into four
groups including control, bortezomib, gemcitabine and bort-
ezomib + gemcitabine (n = 6 or 7). Therapy was started by intra-
peritoneal injections of 100 ml of phosphate-buffered saline (PBS)
(controls), bortezomib (0.8 mg/kg twice weekly) and gemcitabine
(100 mg/kg twice weekly), and was continued for 8 weeks. The
drug concentrations chosen were based on previously reported
maximally effective and tolerable doses of gemcitabine (125 mg/
kg) and bortezomib (1 mg/kg)10,12,15,19. We selected 80% of the
maximum tolerable dose for gemcitabine (100 mg/kg) and bort-
ezomib (0.8 mg/kg), either alone or in combination. At these
doses there were no apparent signs of toxicity. Animals were
euthanized when the mice became moribund; presence of
advanced cancer was proven for every animal. Survival was evalu-
ated from the day of tumour cell injection until death.
Statistical analysis
For the in vivo survival study, statistical significance was analysed
via non-parametric survival statistics through log-rank testing.
Group differences were considered statistically significant at a
P-value of <0.05.
Results
Bortezomib inhibits PaCa cell proliferation
We first investigated the effect of bortezomib on in vitro
proliferation of PaCa cells using the WST-1 assay. Bortezomib
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significantly and dose-dependently inhibited AsPC-1, Panc-1 and
MiaPaCa PaCa cell proliferation.AsPC-1 cells were less sensitive to
bortezomib, as a 10-mM concentration caused 29% and 72%
decrease in cell proliferation at 48 and 96 h incubation, respec-
tively (Fig. 1). Panc-1 and MiaPaCa cells were more sensitive to
bortezomib and responded to treatment almost similarly, with a
10-mM concentration of bortezomib causing an 80% decrease in
cell proliferation at 48 h incubation; after 96 h incubation, the
bortezomib effect was even more pronounced, as at a low concen-
tration of bortezomib (500 nM) the resulting inhibition in cell
proliferation was more than 85% (Fig. 1).
Bortezomib and gemcitabine have additive effects on
inhibition of cell proliferation
Combination effects of bortezomib and gemcitabine on AsPC-1
cell proliferation were measured in vitro. The inhibition in cell
proliferation was 88% and 93% with 10 and 20 mM bortezomib,
respectively; gemcitabine treatment at 10 and 100 mM reduced cell
proliferation approximately 45% by after 72 h of incubation
(Fig. 2). The combination of bortezomib and gemcitabine admin-
istered simultaneously in comparable concentrations was more
effective in inhibiting cell proliferation, and no viable cells were
present after 72 h of incubation (Fig. 2).
Bortezomib and gemcitabine have additive effects on
PARP cleavage
Induction of AsPC-1 cell apoptosis by bortezomib and gemcitab-
ine treatment was analysed via cleavage of PARP, and measured by
Western blot analysis. As depicted in Fig. 3, induction in the
N-terminal cleavage product of PARP (~24 kDa) compared with
control was 6.6-, 2- and 8.5-fold for the bortezomib, gemcitabine
and bortezomib + gemcitabine groups, respectively. We did not
observe any band for the C-terminal cleavage product of PARP in
this setting (data not shown).
Bortezomib and gemcitabine combination treatment
improves animal survival
An in vivo survival study showed no increase in animal survival
over controls after bortezomib treatment alone; an increased sur-
vival was observed after gemcitabine treatment alone, whereas
the bortezomib + gemcitabine combination treatment was most
effective (P < 0.002; Fig. 4). The median survival was 31 days for
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Figure 1 In vitro cell proliferation after treatment with bortezomib. PaCa cell lines AsPC-1, Panc-1 and MiaPaCa were exposed to
bortezomib, and proliferation was determined using the WST-1 reagent after 48 and 96 h incubation. Data are representative of mean values
(n = 6)  standard deviation (SD)
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Figure 2 Effects of bortezomib and gemcitabine combination treatment on ASPC cell proliferation in vitro. Cells were treated with bortezomib
and gemcitabine, either alone or in combination. After 72 h, cell proliferation was measured using the WST-1 reagent. The graphs depict
mean values (n = 4)  standard deviation (SD)
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Figure 3 Effects of bortezomib and gemcitabine treatment on
poly(ADP-ribose) polymerase (PARP) cleavage. (a) AsPC-1 cells
were treated with 10 mM bortezomib or 10 mM gemcitabine, either
alone or in combination, for 24 h. Western blot bands represent the
cellular expression of the N-terminal cleavage product of PARP. (b)
Densitometric analysis of expression of cleaved PARP. Values were
normalized with a-tubulin expression and are depicted in a bar
graph
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Figure 4 Effects of bortezomib and gemcitabine treatment on the
overall survival of mice in vivo. AsPC-1 cells were injected intraperi-
toneally in severe combined immunodeficiency (SCID) mice, and
treatment was started after 12 days with bortezomib (0.8 mg/kg
twice weekly) or gemcitabine (100 mg/kg twice weekly) for 8 weeks.
The curve represents the survival time from the time of the tumour
cell injection
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control and after bortezomib alone, 40 days after gemcitabine
alone, and 48 days in the bortezomib + gemcitabine treatment
group, respectively.
Discussion
Current conventional chemotherapy treatments have shown
limited benefits against PaCa. The pharmacological proteasome
inhibition has become an attractive mechanism for cancer treat-
ment. Bortezomib, a reversible inhibitor of the proteasome, has
been shown to have promising antitumour activity against human
PaCa cells in vitro and in vivo.11,14,15 Bortezomib has also been
shown to enhance the antitumour effects of other chemotherapy
drugs such as docetaxel, cisplatin and gemcitabine in PaCa cells
in vitro.10,12,13,15 Unfortunately, clinical trial results in patients with
metastatic PaCa using bortezomib alone or in combination with
gemcitabine did not result in any apparent improvement in
overall survival when compared with survival expected after gem-
citabine monotherapy.16
In combination therapies of bortezomib with other chemo-
therapeutic agents, the sequence of treatment appears to play an
important role. Fahy et al. reportedmaximum in vitro antitumour
effects in PaCa cells through treatment with gemcitabine followed
by bortezomib indicating that bortezomib works by blocking
endogenous cancer cell survival responses after the chemotherapy
exposure.13 In another study, treatment initiated with bortezomib
followed by the cytotoxic chemotherapeutic agent irinotecan had
the greatest antitumour effects through induction of apoptosis.14
Another study showed a significant antitumour effect in PaCa
with bortezomib and docetaxel administered together.15 In the
previouslymentioned clinical trial of advanced PaCa, bortezomib/
gemcitabine therapy was given according to Nawrocki et al.,15 with
bortezomib administered on day 1, 4, 8 and 11, and gemcitabine
given on day 1, and 8, 1 h apart.16 These studies not only reflect the
challenge of how reliably preclinical models of PaCa can deter-
mine the optimum dosing schedule, but also leave room to specu-
late that a combination treatment approach based on bortezomib
and gemcitabine can be further enhanced by additional antine-
oplastic agents.
Previous studies have reported that human PaCa cell lines
display marked response heterogeneity towards gemcitabine.20
PaCa is clinically characterized as highly resistant to all current
chemotherapy treatments, which includes gemcitabine in the
majority of patients. Therefore, we selected PaCa cell lines more
resistant to gemcitabine, especially AsPC-1 and to a lesser extent
Panc-1 andMiaPaCa, to evaluate the effect of bortezomib on PaCa
cell growth in vitro. Lack of gemcitabine responsiveness combined
with a robust in vivo tumorigenicity were the reasons to use
AsPC-1 cells for the in vivo experimentation. We observed that
bortezomib significantly inhibited AsPC-1 PaCa cell proliferation
in vitro, and that a combination of bortezomib and gemcitabine
was even more effective. Induction in apoptosis caused by bort-
ezomib and gemcitabine has been implicated as the dominant
mediator of the antitumour effect of either agent, respectively.
PARP is a 116-kDa nuclear DNA-binding protein, which is cleaved
to 89-kDa (C-terminal cleavage) and 24-kDa (N-terminal cleav-
age) protein by caspase-3 during the apoptotic process. We
observed that predominantly bortezomib, but also gemcitabine
caused an increase in the 24-kDa N-terminal cleavage product of
PARP; the combination treatment more effectively increased
PARP cleavage than either agent alone. In accordance with these in
vitro antitumor effects, bortezomib + gemcitabine combination
treatment resulted in a significant increase in survival of mice
compared with controls or single agent treatments. Interestingly,
in contrast to the dramatic in vitro antitumour effects of bort-
ezomib alone, it did not yield any survival benefit in vivo. Our
findings are complementing a recent study showing that in vitro
bortezomib alone has antiproliferative and proapoptotic effects
while in vivo it was ineffective in an orthotopic PaCa model.21
The discrepancy between our in vivo combination therapy data
and the negative clinical trial results deserve further comment.
First, the clinical trial did not compare gemcitabine + bortezomib
to gemcitabine alone, but attempted to compare the combination
therapy results to expected survival from historic gemcitabine
monotherapy data; in addition, only patients with an advanced
disease burden were evaluated in this protocol, which precludes
firm conclusions regarding a lack of efficacy in for instance adju-
vant therapy applications.16 Second, the scheduled administration
of both agents in the trial may not be optimal, and the continua-
tion therapy in our in vivo experiment setup may prove more
efficacious. Third, it is possible that the in vivo experimentation
using our quasi-orthotopic model despite its proven and repro-
ducable stepwise pancreas-centred tumour progression18 lacks
clinical relevance. While this concern cannot be refuted, we nev-
ertheless consider the model useful for the preclinical selection of
therapeutic strategies with adjuvant benefit potential; to date,
most cytotoxic agents tested except gemcitabine have shown no
demonstrable survival benefit in this setting while certain combi-
nations indicate greater potential. We plan to continue to utilize
this strategy in our evaluation of combination PaCa therapy.
In conclusion, our study has shown that a bortezomib and
gemcitabine combination can have additive antitumour effects in
vitro, as well as in an experimental PaCa in vivo model. These
findings support the rationale that combination therapy can yield
better results in the treatment of PaCa progression. The observed
combination benefit in vivo remains modest, but provides us both
with a combination therapy baseline against which the value of
adding other antineoplastic agents can be compared, and a mea-
surable mechanism that can be reevaluated after addition of other
therapeutics.
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